Sponsor

SCRI Development Innovations, LLC

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name SCRI Development Innovations, LLC appears in 86 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials86
Recruiting shown1
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerNCT05748834 · lead sponsor · 2023-07-24
RECRUITING
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)NCT06773910 · lead sponsor · 2025-03-11
ACTIVE_NOT_RECRUITING
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent LorlatinibNCT05948462 · lead sponsor · 2023-11-01
WITHDRAWN
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast CancerNCT04699630 · lead sponsor · 2021-05-03
COMPLETED
Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 InhibitorNCT03977467 · lead sponsor · 2019-08-30
COMPLETED
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsNCT02795156 · lead sponsor · 2016-09-28
COMPLETED
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic MalignanciesNCT02649673 · lead sponsor · 2016-03-23
TERMINATED
Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBCNCT02436772 · lead sponsor · 2015-05-13
COMPLETED
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast CancerNCT02291913 · lead sponsor · 2014-12-18
COMPLETED
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate CancerNCT02125084 · lead sponsor · 2014-10-01
COMPLETED
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial MetastasesNCT01934894 · lead sponsor · 2014-05-01
TERMINATED
Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With DocetaxelNCT02035124 · lead sponsor · 2014-04-01
WITHDRAWN
Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)NCT01990209 · lead sponsor · 2014-03-01
COMPLETED
Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to ErlotinibNCT01487265 · lead sponsor · 2014-03-01
COMPLETED
Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung CancerNCT01829113 · lead sponsor · 2013-07-01
COMPLETED
Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or LongerNCT01522833 · lead sponsor · 2012-10-01
COMPLETED
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast CancerNCT01527487 · lead sponsor · 2012-06-01
COMPLETED
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant ChemotherapyNCT01401959 · lead sponsor · 2011-09-23
COMPLETED
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast CancerNCT01048099 · lead sponsor · 2011-01-01
COMPLETED
Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLCNCT01042288 · lead sponsor · 2010-06-01
COMPLETED
SCRI Tissue Testing RegistryNCT00965861 · lead sponsor · 2010-05-01
TERMINATED
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast CancerNCT00894504 · lead sponsor · 2010-02-01
COMPLETED
Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung CancerNCT01027598 · lead sponsor · 2010-01-01
COMPLETED
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast CancerNCT01033032 · lead sponsor · 2009-12-01
COMPLETED
A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung CancerNCT01076504 · lead sponsor · 2009-12-01
COMPLETED
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLCNCT00960297 · lead sponsor · 2009-08-01
TERMINATED
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast CancerNCT00915603 · lead sponsor · 2009-07-01
COMPLETED
Trial of Poor Performance Status Patients (ToPPS)NCT00892710 · lead sponsor · 2009-06-01
COMPLETED
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast CancerNCT00887575 · lead sponsor · 2009-06-01
COMPLETED
Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung CancerNCT00906282 · lead sponsor · 2009-06-01
COMPLETED
Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast CancerNCT00866905 · lead sponsor · 2009-04-01
COMPLETED
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast CancerNCT00825734 · lead sponsor · 2009-03-01
COMPLETED
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast CancerNCT00821886 · lead sponsor · 2009-02-01
COMPLETED
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast CancerNCT00789581 · lead sponsor · 2008-12-01
COMPLETED
Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast CancerNCT00876070 · lead sponsor · 2008-11-01
COMPLETED
Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung CancerNCT00741988 · lead sponsor · 2008-09-01
COMPLETED
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung CancerNCT00695292 · lead sponsor · 2008-06-01
COMPLETED
LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer PatientsNCT00632489 · lead sponsor · 2008-05-01
COMPLETED
Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast CancerNCT00629499 · lead sponsor · 2008-04-01
COMPLETED
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on ErlotinibNCT00609804 · lead sponsor · 2008-03-01
COMPLETED
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)NCT00600015 · lead sponsor · 2008-02-01
COMPLETED
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLCNCT00621049 · lead sponsor · 2007-12-01
COMPLETED
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast CancerNCT00544167 · lead sponsor · 2007-05-01
COMPLETED
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)NCT00545766 · lead sponsor · 2007-05-01
COMPLETED
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLCNCT00456261 · lead sponsor · 2007-03-01
COMPLETED
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast CancerNCT00405938 · lead sponsor · 2006-11-01
COMPLETED
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung CancerNCT00402883 · lead sponsor · 2006-11-01
TERMINATED
Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast CancerNCT00392392 · lead sponsor · 2006-10-01
COMPLETED
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung CancerNCT00305942 · lead sponsor · 2006-03-01
COMPLETED
Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung CancerNCT00308529 · lead sponsor · 2006-03-01
COMPLETED
Topotecan in Combination With Pemetrexed in Patients With Advanced MalignanciesNCT00315861 · lead sponsor · 2006-03-01
COMPLETED
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung CancerNCT00294190 · lead sponsor · 2006-02-01
COMPLETED
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung CancerNCT00294931 · lead sponsor · 2006-02-01
COMPLETED
Trastuzumab and Oxaliplatin in Patients With Metastatic Breast CancerNCT00297596 · lead sponsor · 2006-02-01
COMPLETED
Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast CancerNCT00284180 · lead sponsor · 2006-01-01
COMPLETED
Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung CancerNCT00284154 · lead sponsor · 2006-01-01
COMPLETED
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast CancerNCT00193206 · lead sponsor · 2005-09-01
COMPLETED
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung CancerNCT00193453 · lead sponsor · 2005-07-01
COMPLETED
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung CancerNCT00193414 · lead sponsor · 2005-05-01
COMPLETED
Docetaxel Plus Imatinib Mesylate in Metastatic Breast CancerNCT00193180 · lead sponsor · 2005-05-01
COMPLETED

Drugs studied in this sponsor's trials

51 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing SCRI Development Innovations, LLC as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
carboplatin22
docetaxel14
bevacizumab11
gemcitabine11
trastuzumab10
pemetrexed8
topotecan8
cyclophosphamide7
carboplatin RxCUI 40048 · Lead sponsor in 22 linked trial(s) · 0 currently recruiting 22 trials docetaxel RxCUI 72962 · Lead sponsor in 14 linked trial(s) · 0 currently recruiting 14 trials bevacizumab RxCUI 253337 · Lead sponsor in 11 linked trial(s) · 0 currently recruiting 11 trials gemcitabine RxCUI 12574 · Lead sponsor in 11 linked trial(s) · 0 currently recruiting 11 trials trastuzumab RxCUI 224905 · Lead sponsor in 10 linked trial(s) · 0 currently recruiting 10 trials pemetrexed RxCUI 68446 · Lead sponsor in 8 linked trial(s) · 0 currently recruiting 8 trials topotecan RxCUI 57308 · Lead sponsor in 7 linked trial(s) · 0 currently recruiting 8 trials cyclophosphamide RxCUI 3002 · Lead sponsor in 7 linked trial(s) · 0 currently recruiting 7 trials paclitaxel RxCUI 56946 · Lead sponsor in 7 linked trial(s) · 0 currently recruiting 7 trials irinotecan RxCUI 51499 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 5 trials ixabepilone RxCUI 337523 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials doxorubicin RxCUI 3639 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials epirubicin RxCUI 3995 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials everolimus RxCUI 141704 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials sorafenib RxCUI 495881 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials anastrozole RxCUI 84857 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials cabazitaxel RxCUI 996051 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials capecitabine RxCUI 194000 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials eribulin RxCUI 1045453 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials erlotinib RxCUI 337525 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials estramustine RxCUI 4089 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials fulvestrant RxCUI 282357 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials imatinib RxCUI 282388 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials lapatinib RxCUI 480167 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials

Sponsor roles

lead sponsor82
collaborator4
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.